智通财经APP讯，金活医药集团(01110)公布，预期2025年上半年溢利同比减少约 70%至75%，2024年上半年溢利4560万元。预期公司拥有人应占亏损约人民币450万元，2024年上半年公司拥有人应占溢利约人民币3070万元。
董事会认为集团溢利减少主要是由于从事品牌进口医药及保健产品的中国分销业务的毛利减少约50%至55%，主要由于相关产品的需求在市场有所放缓所致。此减少惟部分给深圳市东迪欣科技有限公司的毛利增加约10%至15% 抵销所致。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.